Newron Pharmaceuticals (NWPHF) Cut to “Hold” at Zacks Investment Research

Newron Pharmaceuticals (OTCMKTS:NWPHF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday, Zacks.com reports.

According to Zacks, “Newron Pharmaceuticals SpA is a biopharmaceutical company. It focuses on the discovery and development of drugs for the treatment of central nervous system disorders and pain primarily in Italy and internationally. Newron Pharmaceuticals SpA is headquartered in Bresso, Italy. “

OTCMKTS:NWPHF opened at $9.25 on Wednesday. Newron Pharmaceuticals has a 12-month low of $7.98 and a 12-month high of $9.25.



About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company offers Xadago (safinamide) for the treatment of Parkinson's disease.

See Also: What is the 52-week high/low?

Get a free copy of the Zacks research report on Newron Pharmaceuticals (NWPHF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Newron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Newron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.